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Abstract
Bovine viral diarrhea virus (BVDV) is the prototype Pestivirus. BVDV infection is distributed worldwide and causes serious
problems for the livestock industry. The thiosemicarbazone of 5,6-dimethoxy-1-indanone (TSC) is a non-nucleoside
polymerase inhibitor (NNI) of BVDV. All TSC-resistant BVDV variants (BVDV-TSCr T1–5) present an N264D mutation in the
NS5B gene (RdRp) whereas the variant BVDV-TSCr T1 also presents an NS5B A392E mutation. In the present study, we carried
out twenty passages of BVDV-TSCr T1–5 in MDBK cells in the absence of TSC to evaluate the stability of the resistance. The
viral populations obtained (BVDV R1–5) remained resistant to the antiviral compound and conserved the mutations in NS5B
associated with this phenotype. Along the passages, BVDV R2, R3 and R5 presented a delay in the production of cytopathic
effect that correlated with a decrease in cell apoptosis and intracellular accumulation of viral RNA. The complete genome
sequences that encode for NS2 to NS5B, Npro and Erns were analyzed. Additional mutations were detected in the NS5B of
BVDV R1, R3 and R4. In both BVDV R2 and R3, most of the mutations found were localized in NS5A, whereas in BVDV R5, the
only mutation fixed was NS5A V177A. These results suggest that mutations in NS5A could alter BVDV cytopathogenicity. In
conclusion, the stability of the resistance to TSC may be due to the fixation of different compensatory mutations in each
BVDV-TSCr. During their replication in a TSC-free medium, some virus populations presented a kind of interaction with the
host cell that resembled a persistent infection: decreased cytopathogenicity and viral genome synthesis. This is the first
report on the stability of antiviral resistance and on the evolution of NNI-resistant BVDV variants. The results obtained for
BVDV-TSCr could also be applied for other NNIs.
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Introduction
Bovine viral diarrhea virus (BVDV), along with classical swine
fever virus and border disease virus, is a member of the genus
Pestivirus. This genus belongs to the family Flaviviridae, which also
includes the genera Hepacivirus (hepatitis C virus) and Flavivirus
(yellow fever virus, Dengue fever virus and West Nile virus).
BVDV infection is distributed worldwide and tends to be
endemic in many countries [1], [2]. In Argentina, the prevalence
of BVDV antibodies in adult cattle is around 70% [3], [4]. BVDV
infections lead to a reduction in milk production, lower conception
rates, respiratory disorders and death of the animals that acquire
the acute infection, thus causing serious economic losses for the
livestock industry. Moreover, fetal infection leads to persistently
infected cattle, which are generally smaller, are more susceptible to
other infections and eventually develop a lethal mucosal disease.
BVDV is an enveloped single-stranded (+) RNA virus. Its
genomic RNA is about 12.5 kb long and consists of a single open
reading frame (ORF) flanked by 59 and 39 non-translated regions
(NTRs). The ORF encodes a polyprotein of approximately 3,900
amino acids that is co- and post-translationally processed to
mature viral proteins by cellular and viral proteases. The viral
proteins are sequentially designated Npro, C, Erns, E1, E2, p7,
NS2, NS3, NS4A, NS4B, NS5A and NS5B. The autoprotease
Npro is a non-structural (NS) protein that plays a role in blocking
IFN-a/b induction [5–8]. The capsid protein (C) is followed by
three virion glycoproteins: Erns, E1, and E2. Erns encodes an
RNase that is secreted in nonvirion forms [9] and targets
extracellular RNA, a major viral signal that triggers IFN synthesis
[10], [11]. The rest of the polyprotein is processed to NS proteins,
of which only NS3 through NS5B are required for RNA
replication [12], [13]. NS2, together with the amino terminus of
NS3, functions as an autoprotease that cleaves the NS2-NS3
junction of the polyprotein. This cleavage is required for RNA
replication and is linked to BVDV cytopathogenicity and
pathogenesis [14], [15]. NS3 is a multifunctional protein with a
helicase/nucleoside triphosphatase and serine protease activity
responsible for all downstream polyprotein cleavages [16–19].
NS4A is tightly associated with NS3 and serves both as a cofactor
for NS3 protease activity and as a tether that localizes NS3 to
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membranes [17], [20]. NS4B is believed to function as an integral
membrane scaffold upon which the replicase complex (RC)
assembles [21]. NS5A is a phosphoprotein that plays an essential
role in BVDV replication and pathogenesis [22–24]. Finally,
NS5B is the viral RNA-dependent RNA polymerase that catalyzes
viral RNA synthesis [25–29].
BVDV isolates are categorized into two biotypes according to
their effect on cultured cells: noncytopathic (ncp) isolates, which
infect permissive host cells without causing cell death, and
cytopathic (cp) isolates, which produce rapid cytopathic effects
(CPE) and kill cells [30]. Only ncp isolates are able to establish the
persistent infection. This difference is associated with distinct
interactions between each biotype and the host innate immune
response against the viral infection, which is active early during
gestation. Cp biotypes emerge from ncp biotypes exclusively in
persistently infected animals and are invariably associated with the
mucosal disease [12], [31]. The induction of apoptosis plays a
significant role in the pathology of the cp isolates both in infected
cell cultures and in the clinical manifestations of the mucosal
disease [32–35].
The thiosemicarbazone of 5,6-dimethoxy-1-indanone (TSC) is a
non-nucleoside polymerase inhibitor of BVDV (EC50
1.860.6.mM) [36–38]. In a previous study, we selected five
independent populations of TSC-resistant BVDV (BVDV-TSCr;
T1–5) (TSC EC50.80.0 mM). All of them carry an NS5B N264D
mutation, whereas BVDV-TSCr T1 also shows an NS5B A392E
mutation [38].
Studies on the resistance to an antiviral agent are highly
important for the development and therapeutic application of such
antiviral agent. Given that the impact of resistance is difficult to
predict, it is important to evaluate not only the emergence of
resistance but also its stability and the effect of the associated
mutations on the viral replicative fitness in an antiviral-free
environment. Therefore, the aim of the present work was to
evaluate the stability of the resistance to TSC. To this end, we
carried out 20 passages of BVDV-TSCr T1–5 in the absence of
TSC. We also describe the molecular and biological character-
ization of the viral populations obtained, in terms of infectious
virus production and cytopathogenesis.
Materials and Methods
Cells and virus
Madin Darby bovine kidney cells (MDBK NBL-1; ATCC
CCL-22) were grown in Eagle’s Minimal Essential Medium
(EMEM), supplemented with 10% c irradiated fetal bovine serum
(FBS, PAA Laboratories, Pasching, Austria) (growing medium).
BVDV type 1 NADL strain, cytopathic biotype (BVDV-1, ATCC
VR 534) was provided by Dr Laura Weber, INTA Castelar,
Argentina. Wild type (wt) BVDV p0 was obtained after three
successive steps of biological cloning of BVDV NADL in MDBK
cells. TSC-resistant BVDV (BVDV-TSCr T1–5) were obtained
from wt BVDV p0 after ten passages in MDBK cells with
increasing concentrations of TSC [38].
Passages of BVDV-TSCr in the absence of TSC
MDBK cells were infected with BVDV-TSCr T1–5 at a
multiplicity of infection (MOI) of 0.01. Cell cultures were
incubated in infection medium (infection medium: EMEM
supplemented with 2.5% Donor Horse Serum -DHS- Gibco) in
a 5% CO2 incubator at 37uC until cell monolayers presented 80–
90% of viral CPE. The supernatant was collected and clarified by
centrifugation for 10 min at 1,0006g at 4uC. After titration of the
virus in MDBK cells, the virus was used to infect new cell
monolayers to generate the next passage. This procedure was
repeated twenty times, and the virus obtained from each BVDV-
TSCr T1–5 was named BVDV R1–5.
Plaque reduction assay for BVDV
To evaluate the antiviral activity of TSC against BVDV R1–5,
MDBK cells were seeded in growing medium at a density of
1.36105 cells per well in a 24-well plate and incubated for 24 h at
37uC in a 5% CO2 incubator. Then, cells were infected with
approximately 100 plaque-forming units (PFUs) of BVDV R1–5 or
wt BVDV p0. Following 1 h of adsorption at 37uC, the inoculum
was removed, cell monolayers were washed twice with phosphate-
buffered saline (PBS), and 1 ml of overlay medium (2.5% DHS
and 0.8% methylcellulose) containing 80 mM of TSC was added in
each well. Mock-infected cells with and without TSC, and infected
cells without TSC were included as controls. After 72 h of
incubation at 37uC with 5% CO2, cells were fixed with formalin
10%, stained with 0.75% crystal violet, and the viral plaques
counted.
Apoptosis measurements
MDBK cells were seeded in a 24-well plate as described above.
After 24 h in a 5% CO2 incubator at 37uC, cells were infected
with wt BVDV p0 or R1–5 (MOI 0.01). Following 1 h of
adsorption at 37uC, the inoculum was removed, cell monolayers
were washed twice with PBS and 1 ml of infection medium was
added in each well. Mock-infected cells were included as controls.
After 48 h of incubation at 37uC with 5% CO2, apoptosis was
measured in infected and mock-infected cell cultures.
For apoptosis measurements, PE Annexin V Apoptosis Detec-
tion Kit I (BD Pharmigen, NJ, USA) was used following the
manufacturer’s instructions. Briefly, supernatants from infected
and mock-infected cells were harvested and cells in the monolayer
were collected by trypsinization and resuspended in 0.5 ml of
infection medium. Adherent and floating cells were pooled and
pelleted by centrifugation at 5006g for 10 min. Pelleted cells were
washed twice with 0.5 ml of cold PBS. Before the second
centrifugation (5006g, 10 min), cells were counted in a Neubauer
chamber. To obtain the dead-cell control for apoptosis measure-
ments, one mock-infected cell suspension was heated at 65uC for
30 min. Then, cells were resuspended in binding buffer
(46106 cells/ml) and 100 ml of each cell suspension was stained
with 5 ml Annexin V (conjugated with Phycoerythrin- PE-) and
5 ml 7-Amino-Actinomycin (7AAD) and incubated for 15 min at
room temperature in the dark. Finally, 400 ml of binding buffer
was added and the cells were analyzed by flow cytometry
(PARTEC, PAS-III). PE Annexin V and 7AAD fluorescence
was collected at FL 2 (550–600 nm) and FL4 (640–700 nm)
channels, respectively. Histograms and density plots of 20,000
events were obtained and analyzed with WinMDI 2.9 software
[39].
At 48 h p.i. some infected cultures already presented viral CPE,
which is caused by cell apoptosis. The number of cells that would
have died by this mechanism and could no longer be detected was
estimated by the difference between the number of cells counted in
a Neubauer chamber in the mock-infected cultures (MIC) and
those counted in the infected ones (IC) (A: Nu undetected dead cells =
Nu cells MIC 2 Nu cells IC). Then, the number of apoptotic cells in
each infection (i.e. in the remaining adherent and floating cells)
was quantified by AnV binding and flow cytometry as stated above
(B: Nu apoptotic cells = % AnVpos6Nu cells IC/100). Finally, the
total cells that would die by each viral infection was estimated as %
dead cells (normalized to uninfected) = (A+B)6 100/Nu cells MIC.
Stability End Evolution of TSC-Resistant BVDV
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Multiple-step growth curve
To quantify the infectious virus produced by BVDV R1–5 in the
absence of TSC, MDBK cells were seeded in a 24-well plate as
stated above and infected with BVDV R1–5 or wt BVDV p0 (MOI
0.01). Following 1 h of adsorption at 37uC, the inoculum was
removed, cell monolayers were washed twice with PBS, and 1 ml
of infection medium was added to each well. The culture
supernatant was collected every 24 h for 7 days and clarified by
centrifugation for 10 min at 1,0006g at 4uC. The infectious virus
in each sample was quantified by the PFU method in MDBK cells.
Given that BVDV R4 and R5 showed CPE and levels of cell
apoptosis similar to those of BVDV R1 and R2, respectively (see
results section), they were not included in the following assays
(unless otherwise indicated).
Fluorescent microscopy
MDBK cells were seeded in a 24-well plate at a density of 1.3
6105 cells per well containing a circular slide cover of 10 mm in
diameter. After 24 h in a 5% CO2 incubator at 37uC, cells were
infected with BVDV R1, R2, R3 or wt BVDV p0 (MOI 0.01).
Following 1 h at 37uC, the inoculum was removed, cell
Table 1. Oligonucleotides used for retrotranscription (RT) reactions and PCR amplifications.
Primer Sequence (59-39) Position in the genome
Npro region
PR S1 GCCCACTGTATTGCTAC 344–360
PR AS1 CCCCTTTCTAGTCTGTCG 937–954
Erns region
PR S2 AGGAATCACGCAAGAAACTG 1,116–1,135
PR AS2 GTCACTAGCCCTATCATACC 1,539–1,558
PR S3 TTGAACCCTGGATTCTAGTC 1,455–1,474
PR AS3 AATTTCCCAGGGCCGAC 1,970–1,986
NS2-NS3 region
RT1 CTTCCCCTTCCTTATAGAGAG 8,261–8,281
PR S4 AATACTGGTTTGACCTGGAG 3,435–3,454
PR AS4 CGCCAGTTCTTTCAGTTCAGT 7,646–7,666
SR S5 CGCTGAGTCCATATTAGTGGT 3,481–3,501
SR AS5 ACTGAACTTATCCCGCCT 5,605–5,622
SR S6 CTGCCGTGTGTAAGAAGAT 5,427–5,445
SR AS6 GTCTTCTAGTCTCTGGTCCT 7,575–7,594
NS4A-NS4B region
RT2 GTAGTGTTAGCTTGAGGTAGATA 12,477–12,498
PR S7 TAGACTGGCCTGATCCTG 7,401–7,418
PR AS7 GTTGGCAATCTGATCCTCT 8,826–8,844
NS5A-NS5B region
RT2 GTAGTGTTAGCTTGAGGTAGATA 12,477–12,498
PR S8 CTGTATGGGGTTTACTACAAAGG 8,567–8,589
PR AS8 TCTTCTTGAGGTGGACGG 12,417–12,434
SR S9 CTGTATGGGGTTTACTACAAAGG 8,567–8,589
SR AS9 TTGGTAAGCTGATGCCATGTG 10,295–10,315
SR S10 AGGAGATGTTGGAGAGGTAA 10,090–10,109
SR AS10 TCTTCTTGAGGTGGACGG 12,417–12,434
Sequences and positions in the genome of BVDV NADL of the oligonucleotides designed and used for RT reactions and PCR amplifications of Npro, glycoprotein Erns
and non-structural proteins coding region. Positions in the BVDV genome are according to BVDV NADL genome sequence GenBank accession no AJ133738.1.
doi:10.1371/journal.pone.0100528.t001
Figure 1. Antiviral activity of TSC against BVDV R1–5. BVDV-TSC
r
T1–5 were propagated in MDBK cells in the absence of TSC during 20
passages. The antiviral activity of 80 mM of TSC against the viral
populations obtained (BVDV R1–R5) and wt BVDV p0 was evaluated by
plaque reduction assays. White and black bars indicate the number of
viral plaque forming units (PFUs) formed in the presence or in the
absence of TSC, respectively. (TSC vs untreated: R1 p= 0.560; R2
p= 0.054; R3 p= 0.449; R4 p= 0.382; R5 p= 0.002; p0 p= 0.003).
doi:10.1371/journal.pone.0100528.g001
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monolayers were washed twice with PBS, and 1 ml of infection
medium was added to each well. At 24, 48 and 72 h p.i., the cell
culture medium was removed and cell monolayers were fixed with
4% formaldehyde/PBS for 15 min at room temperature. After
washing three times with PBS, cultures were incubated with 0.5 ml
of blocking buffer (10% Bovine seralbumin -BSA-; 0.3% Triton X-
100 in PBS) for 30 min. Then, slide covers were removed and
incubated overnight at 4uC with 30 ml of anti-BVDV NS3
Monoclonal Antibody (diluted 1:1000 in PBS 0.1% Triton X-
100; 1% BSA), kindly provided by Dr Alejandra Capozzo
(Instituto de Virologı´a, INTA, Castelar, Buenos Aires, Argentina).
Slide covers were washed three times with PBS and incubated
protected from light for 2 h at room temperature with Alexa Fluor
488 Goat Anti-Mouse antibody (Invitrogen) (diluted 1:1000 in PBS
0.1% Triton X-100; 1% BSA). Afterwards, cells were washed
three times with PBS and the nucleus stained with 300 ml of DAPI
(Invitrogen) (dilution 1:100) for 5 min. The slides were mounted
with FluorSave (Calbiochem) and the cells were observed with a
Nikon Eclipse 80i microscope with a 206 objective (numerical
aperture 0.40). The images were captured with a digital camera
(Nikon Digital Sight DS-Qi1Mc) and processed using ImageJ
software.
Viral RNA production
MDBK cells were seeded in a 24-well plate as stated above.
After 24 h in a 5% CO2 incubator at 37uC, cells were infected
with BVDV R1, R2, R3 or wt BVDV p0 (MOI 1). Following 1 h of
adsorption on ice, the inoculum was removed, cell monolayers
were washed twice with PBS, and 1 ml of infection medium was
added to each well. After 24 h of incubation at 37uC, intracellular
RNA was extracted with TRIzol reagent (Gibco-BRL, CA, USA).
RNA was retrotranscribed with random hexamers (Biodynamics)
Figure 2. Apoptosis measurements. MDBK cells were infected with wt BVDV p0 or BVDV R1–5 (MOI 0.01) and at 48 h p.i. apoptotic cells were
measured by incorporation of PE Annexin V and 7AAD dyes and analyzed by flow cytometry. Mock-infected cultures were added as control.
Representative density plots (20,000 events) obtained with WinMDI software are displayed. Quadrants delimitating positive (pos) and negative (neg)
events are shown and the percentage of events in each quadrant is indicated. The populations of PE Annexin V2/7AAD2, PE Annexin V+/7AAD2
and PE Annexin V+/7AAD+ correspond to viable cells, early apoptotic cells, and late apoptotic cells.
doi:10.1371/journal.pone.0100528.g002
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at 37uC for 90 min, using 0.5 U/ml M-MLV reverse transcriptase
(Promega, Madison, WI, USA), and quantified by Real-time PCR.
Real-time PCR
To measure the intracellular viral RNA (ivRNA), a 108-bp
fragment from the 59NTR was amplified with the following
oligonucleotides: 59NTR forward 59GAGGCTAGC-
CATGCCCTTAGT39 and 59NTR reverse 59TCGAACCACT-
GACGACTACCCT39. The reaction was carried out in 2X Power
SYBR Green PCR Master Mix (Applied Biosystems, UK) in an
ABI 7500 apparatus (Applied Biosystems), using the following
experimental run protocol: 10 min of activation at 95uC, followed
by 45 cycles of amplification and quantification (15 sec at 95.0uC,
1 min at 60.0uC and 35 sec at 78.5uC) during which the SYBR
GREEN signal was measured. To normalize target amplification
data, a 91-bp fragment of bovine b-actin mRNA was amplified
simultaneously in each sample and used as endogenous control
(forward oligonucleotide: 59CCCACACGGTGCCCATCTAT39
and reverse oligonucleotide: 59 CCACGCTCCGTGAG-
GATCTTC39). Each sample was tested in triplicate and both
positive and negative controls were included.
Data were analyzed by means of the relative standard curve
method [40] to quantify the ivRNA at 24 h p.i. in the cell cultures
infected with BVDV R1, R2 and R3 in relation with those infected
with wt BVDV p0.
Sequencing
Total RNA was extracted with TRIzol reagent (Gibco-BRL)
from wt BVDV p0, BVDV-TSCr T1–5 and BVDV R1–5 virus
suspensions obtained from clarified supernatants of infected cells.
The RNA obtained was denatured at 70uC for 5 min and primed
with the designed specific oligonucleotides (Table 1). The reverse
transcription reaction was performed at 42uC for 90 min, using
10 U/ml of ArrayScriptTM Reverse Transcriptase (Ambion, Inc.).
The PCR fragments that cover the complete coding region of all
the non-structural proteins (Npro, NS2-NS5B) and the glycopro-
tein Erns were obtained using specific oligonucleotides (Table 1)
by PCR amplification with 0.025 U/ml of PFU DNA polymerase
(Promega). Both DNA strands were sequenced using an ABI
ABI3130XL sequencer 131 (Applied Biosystems; Unidad de
Geno´mica, Instituto de Biotecnologı´a, INTA, Castelar, Buenos
Aires, Argentina). The sequences were aligned using ClustalX 1.83
Figure 3. Infection with BVDV R2, R3 and R5 leads to a decrease
in dead cells. MDBK cells were infected with wt BVDV p0 or BVDV R1–5
(MOI 0.01) and at 48 h p.i. apoptotic cells were measured as stated in
Figure 2. Considering the differences in CPE between each viral
infection, the total cells that would die by viral CPE was estimated (see
Materials and Methods Section). The results are summarized in a bar
graph as mean 6 SD of % dead cells in relation to the mock-infected
culture. *p,0.050; Student’s t test vs wt BVDV p0.
doi:10.1371/journal.pone.0100528.g003
Figure 4. Multiple-step growth curve. MDBK cells were infected
with wt BVDV p0 or BVDV R1–5 (MOI 0.01). The viral progeny in the
culture supernatant was collected every 24 h for 7 days and titrated by
PFU. Viruses with altered CPE (BVDV R2, R3, and R5) are displayed in
dashed lines.
doi:10.1371/journal.pone.0100528.g004
Figure 5. MDBK cells infected with wt BVDV and BVDV R
viruses. MDBK cells were infected with wt BVDV p0, BVDV R1, R2, or R3
(MOI: 0.1) and IF-stained using a monoclonal antibody against the NS3
protein at 24, 48 and 72 h p.i. The nucleus was stained with DAPI.
Images were taken with a 206objective (numerical aperture 0.40) and
processed using ImageJ software (the nuclei were pseudocolored with
red for better illustration).
doi:10.1371/journal.pone.0100528.g005
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[41], edited with BioEdit v 7.0.9.0 [42] and compared with the
BVDV strain NADL (p0 and GenBank accession no. M31182.1;
AJI33738.1; NP_776270.1; NP_776271.1; NC_001461.1).
Statistical analysis
The results were analyzed by Student’s t test using InfoStat
version 2011 [43]. A statistically significant difference was
considered if p values were less than 0.050.
Results
The resistance to TSC is conserved after 20 passages
BVDV R1–5 were obtained after 20 passages of BVDV-TSC
r
T1–5 in the absence of TSC. BVDV R1–4 were not significantly
inhibited by TSC, whereas wt BVDV p0 was completely inhibited
(TSC vs untreated: R1 p= 0.560; R2 p= 0.054; R3 p= 0.449; R4
p= 0.382; p0 p= 0.003) (Figure 1). However, with the number of
PFUs analyzed, BVDV R5 showed a reduction in the number of
viral plaques of approximately 44%, suggesting a slight decrease in
drug resistance (TSC vs untreated: R5 p= 0.002).
A delay in CPE production is observed in some viral
populations during passages
The infection of MDBK cells with wt BVDV NADL cp at a
MOI of 0.01 required 48 h of incubation at 37uC to reach 80–
90% of CPE in the cell monolayer. However, along the passages of
BVDV-TSCr T1–5 in the same conditions, some viral populations
showed a delay in producing CPE. To reach 80–90% of CPE, the
infections with BVDV-TSCr T2 and T5 required 72 h of
incubation from the 1st to the 3rd passage and then 120 h of
incubation from the 4th to the 20th passage. Similarly, BVDV-
TSCr T3 required 120 h of incubation from the 13
th to the 20th
passage. This delay in producing CPE was also observed in the
growth of viral plaques when the infected cultures were incubated
in semi-solid medium. BVDV R2, R3, and R5 needed 72–96
additional hours of incubation to properly exhibit the viral
plaques.
The delay in producing CPE is correlated with a reduced
induction of apoptosis in MDBK cells
BVDV cp isolates kill cells by triggering apoptosis [30], [32],
[44]. In accordance with the microscopic observations of the viral
CPE, the infection of MDBK cells with BVDV R1 or R4 produced
levels of apoptosis similar to those produced by wt BVDV p0
(13.1%, 10.8%, and 11.0% of PE Annexin-positive cells,
respectively), whereas the infections with BVDV R2 and R5
produced lower level of apoptosis (5.7% and 5.5% of PE Annexin-
positive cells, respectively). BVDV R3 showed an intermediate
value (9.1% of PE Annexin-positive cells) (Figure 2).
Due to viral CPE, the number of remaining cells at 48 h p.i. in
the cultures infected with wt BVDV p0, R1 or R4 was lower than
that in the cultures infected with BVDV R2, R3 or R5 (2.4–
3.06105 and 4.8–5.56105, respectively) and that in mock-infected
cultures (6.46105). Taking into account that apoptotic cells could
be quantified only in the remaining adherent and floating cells, the
total number of cells that would die by viral CPE in each infection
was estimated (see Materials and Methods Section). Having
considered the differences in CPE between each viral infection, the
results showed that the number of cells that would die by BVDV
R2, R3 and R5 infections was markedly lower than that in wt
BVDV p0 infection (15.6%, 27.5%, 15.5% and 48.6% of
estimated dead cells, respectively) (Figure 3).
The delay in CPE is not caused by a decreased infectious
virus production
Although some viral strains produced no CPE, all viral
populations showed the highest titers of infectious virus at 48 h
p.i. (Figure 4). At that time, most BVDV R (R1 and R3–5) showed
slightly higher virus titers (approximately three times higher) than
wt BVDV p0, but, notably, BVDV R2 showed viral titers
approximately 30 times higher.
On the other hand, wt BVDV p0, R1 and R4 showed a marked
decrease in viral titers at 72 h p.i., consistent with the lack of viable
host cells as a result of the viral CPE. However, MDBK cells
infected with R2, R3 and R5 continued producing infectious virus
for at least four additional days.
In addition, expression of the NS3 antigen was monitored by
indirect immunofluorescence. In accordance with the results
described above, cell monolayers infected with BVDV R2 or R3
were still confluent until 72 h p.i and maintained a continuous
production of NS3 (Figure 5).
Viruses that have a delayed CPE exhibit less
accumulation of viral RNA
One of the factors that contribute to cell apoptosis and viral
cytopathogenicity is the accumulation of viral RNA in the cells
infected with cp BVDV [45]. In line with this, our results showed
that the ivRNA levels in BVDV R2 and R3 infections were lower
than those of wt BVDV p0 and R1. BVDV R2, which together
with BVDV R5 exhibited the lowest level of cell apoptosis in the
infected cultures, also presented the lowest level of ivRNA
accumulation (approximately three times lower than wt BVDV
p0). On the other hand, BVDV R3, which showed an intermediate
level of decrease in cell apoptosis, also presented intermediate
levels of ivRNA (Figure 6).
Resistance mutations are conserved and additional
substitutions were fixed in BVDV R1–5
The nucleotide sequence of Npro, Erns and the complete NS
region of wt BVDV p0, BVDV-TSCr T1–5 and BVDV R1–5
genomes were obtained by direct sequencing (GenBank accession
numbers KJ608467-KJ608499).
After 20 passages without TSC, the nucleotide sequences of the
genomic region that codifies the NS5B protein showed that BVDV
R1–5 conserved the mutations previously associated with the
Figure 6. Viral RNA production. MDBK cells were infected with wt
BVDV p0, or BVDV R1, R2 or R3 (MOI 1) and the intracellular viral RNA
(ivRNA) was quantified at 24 h p.i. by real-time PCR. For each infection
with BVDV R viruses, the results are expressed as ivRNA relative to wt
BVDV p0. Mock-infected cells were added as control in each
experiment. The results are shown as mean 6 SD from two
independent experiments in triplicate. *p,0.050; Student’s t test vs
wt BVDV p0.
doi:10.1371/journal.pone.0100528.g006
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Figure 7. Molecular characterization of BVDV R1–5. The complete nucleotide sequence of the Erns, Npro and NS region from wt BVDV p0,
BVDV-TSCr T1–5 and BVDV R1–5 genomes was obtained by direct sequencing. The nucleotide sequences are arranged in three or four codons and the
position in the genome of the first nucleotide of each group of sequences is indicated above according to the complete genome of BVDV (GenBank
accession no. NC_001461.1). Only the genome regions which showed mutations are displayed. Each BVDV-TSCr T-R pair is shown in gray or white
rows and, for non-synonymous mutations, amino acid changes are indicated below the corresponding nucleotide sequence, indicating the number
of amino acids for each protein. Viruses that showed altered CPE (BVDV R2, R3 and R5) are indicated in boldface.
doi:10.1371/journal.pone.0100528.g007
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resistance to TSC [38]: A10,982G (N264D) in BVDV R1–5
and C11,367A (A392E) in BVDV R1 (which showed mixed
populations of nucleotides A/G and C/A in positions 10,982 and
11,367, respectively) (Figure 7).
Secondly, several mutations were fixed along the sequences
studied: in BVDV R1: NS2 G5,207A (G472R); in BVDV R2: Erns
T1,315Y (Y: mix of T and C), NS5A A8,731G (I9M), NS5A
G8,860A, NS5A A9,617T (N305Y), and NS5B C11,987T; in
BVDV R3: Erns T1,706G (C171G), NS4B A7,745R (R: mix of A
and G) (E28G), NS5A A9,287R (K195E), NS5A G9,812R
(E370K), NS5B A10,592G (I134V) and A10,975G (I261M); in
BVDV R4: NS3 T6,912C, NS5A T9,285Y (M94T), NS5B
C10,768T and NS5B G11,300C (K370N). Some other mutations
(not associated with antiviral resistance) were conserved between
BVDV-TSCr T1–5 and their respective BVDV R1–5: NS5B
A10,723G in T1-R1 and NS5A T9,234C in T2-R2 (V177A).
Notably, no new mutation was detected in BVDV R5 after 20
passages. However, whereas BVDV-TSCr T5 presented mixed
population of T and C in nucleotide T9,234 (NS5A V177), BVDV
R5 presented only C (A177) (Figure 7). This suggests that this
mutation would have become fixed in the viral population during
the passages in the absence of TSC.
Discussion
We have previously reported the selection of TSC-resistant
BVDV mutants (BVDV-TSCr T1–5) with mutations in NS5B (T1–
5: N264D; T1: A392E) [38]. In the present study, we performed 20
passages of BVDV-TSCr T1–5 in the absence of TSC to analyze
their genetic stability.
The resistance to TSC remained stable and mutations in NS5B
associated with resistance were conserved in all the viral
populations obtained (BVDV R1–5). However, BVDV R1–5
produced higher titers of infectious virus than wt BVDV p0 and,
along the passages in the antiviral-free environment, three out of
the five viral populations (BVDV R2, R3 and R5) showed a delay
in producing CPE.
It is known that drug-resistant mutants may have fitness costs in
the absence of the selecting drug, but the occurrence of
compensatory mutations may allow them to partially or even
completely regain fitness [46–48]. A previous work has shown that
BVDV variants that carry the NS5B N264D mutation, which
confers resistance to TSC and to other non-nucleoside polymerase
inhibitors (NNI) [49], [50], present a replication disadvantage
when competing with the wild-type (wt) virus in an antiviral-free
environment [51]. In the present work, the replication of BVDV-
TSCr in the absence of TSC led to the fixation of different
mutations along the NS region that could compensate for the
reduced fitness caused by the N264D mutation and confer some
stability to the TSC-resistant phenotype. Specifically, mutations
were detected in NS2 (BVDV R1), NS4B (BVDV R3), NS5A
(BVDV R2–5) and NS5B (BVDV R3 and R4). Particularly,
mutation NS5B I261M (BVDV R3) has been reported to
compensate for the reduced fitness caused by the N264D mutation
and to confer resistance to other BVDV NNI [49–51]. Additional
mutations suggest that the effect of the NS5B N264D mutation on
viral fitness could be also counterbalanced by a change in other
NS proteins. Because BVDV-TSCr were not replicated under a
selective pressure, these additional mutations may have resulted
from the genetic drift during the passages and could have also
been detected in the wild type virus if it had been passaged in
conditions similar to those of BVDV-TSCr.
As mentioned above, BVDV R2, R3, and R5 showed a delay in
producing CPE. The cp biotypes of BVDV induce cell death by
apoptosis [44], [52], triggered by the accumulation of viral double-
strand RNA [45], [53] and the continuous expression of NS3, the
cleaved form of the nonstructural protein NS2-3 [14], [15].
Although viral RNA production in cp BVDV infections is higher
than that in ncp ones, both show similar production of infectious
viral particles [18], [53–56]. Accordingly, cell cultures infected
with BVDV R2, R3 and R5 showed a decrease in the induction of
apoptosis and in the accumulation of viral RNA. However, BVDV
R1–5 produced higher infectious virus titers than wt BVDV p0,
and due to host cell survival, BVDV R2, R3 and R5 produced viral
antigens and infectious viral progeny for at least four additional
days.
BVDV NADL cytopathogenicity is determined by an in-frame
insertion in the NS2 coding region of a 270-nucleotide cellular
mRNA sequence (called cIns), which modulates NS3 production
and upregulates RNA replication [18]. As for other cp BVDV
strains, the deletion of the inserted host-derived sequences could
lead to reversion to the ncp phenotype [54], [57], [58]. In this
work, BVDV R1–5 showed no deletion (or insertion) in the cIns or
in any of the viral sequences. In addition, BVDV R2, R3 and R5
showed no amino acid changes in NS2 or NS3, whose bond
cleavage is required for RNA replication and is linked to BVDV
cytopathogenicity [14], [15]. No amino acid changes were
detected in NS3-cofactor NS4A or in Npro and Erns, which
may play a role in blocking IFN induction and therefore could also
affect the viral CPE [5–8], [10], [11]. This suggests that the delay
of BVDV R2, R3 and R5 in producing CPE may not result from
an alteration in the production or function of these viral proteins.
On the other hand, BVDV R3 showed a mutation in NS4B
(E28G). This protein would also play a role in BVDV
cytopathogenicity [21], and substitutions for residue NS4B Y15
have been shown to attenuate viral CPE despite NS3 production
[55].
Interestingly, most of the additional amino acid changes found
in BVDV R2 and R3 and the only one detected in BVDV R5 were
in NS5A. BVDV NS5A is a zinc metalloprotein essential for the
formation of a functional replicase complex [22], [59], [60] that
seems to inhibit TNF-a and double-strand RNA-induced NF-kB
activation, which is involved in inflammation, innate immune
response, cell survival, and pathogenesis or persistence of BVDV
infections [24], [61], [62]. BVDV NS5A is composed of three
domains. Mutations were found in domain I (I9M in BVDV R2,
V177A in BVDV R5 and K195E in BVDV R3) and domain II
(N305Y in BVDV R2 and E370K in BVDV R3), both critical for
RNA replication [22], [63]. Thus, the additional mutations in
NS5A could alter its function during viral RNA replication and/or
interfere with its interaction with cellular proteins involved in the
induction of apoptosis, thus leading to the observed reduction in
viral cytopathogenesis.
To our knowledge, this is the first report on the stability and
evolution of non-nucleoside polymerase inhibitor-resistant BVDV.
The study of the TSC-resistant viruses that showed reduced CPE
and prolonged virus production may be an interesting tool to learn
more about the virus-cell interaction, viral cytopathogenesis,
attenuation and persistence. Further studies and reverse genetic
experiments would be needed to identify the specific phenotype of
each of the additional mutations observed.
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